See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
Volatility is no fun if you're a stock market investor — and there's been plenty of that so far in 2025. But it's important to keep in mind that stocks in general have always produced strong returns over time.
The S&P 500 has risen by about 91% over the past five years alone, despite major headwinds ranging from COVID-19 and soaring inflation to President Donald Trump's current tariff threats. The Dow is up about 62% over the same time frame, while the Nasdaq has roughly doubled in value.
Discover More:
Find Out:
Those are all very good returns, but they pale in comparison to the best performing stocks. If you were fortunate enough to invest in one of those, you would have seen your money rise more than 10-fold in the last half-decade.
One reason some of the best performers rose so fast is that they traded at very low values five years ago — in some cases around $1 a share. Any spike in value would represent a major percentage gain.
An example is GameStop, the gaming and entertainment company whose stock could be purchased for a little more than $1 a share in June 2020. GameStop grabbed headlines in early 2021 when professional investors shorted the stock, figuring it would go down in value. But as EBSCO noted at the time, a 'wave' of amateur investors started buying up shares and helped the stock soar by more than 1,500% in a matter of weeks.
Today, GameStop trades for around $30 a share. If you had invested $100 in the company in early June of 2020, your investment would now be worth more than $2,500.
Here's a look at the massive returns you would have gotten by investing in 10 of the top performing stocks over the past five years. Each has risen by at least 1,000% and boasts a current price of roughly $30 a share or more.
Trending Now:
Closing price June 8, 2020: $3.10 per share
Closing price June 4, 2020: $132.41
5-year return: 4,171%
Closing price June 8, 2020: $1.25
Closing price June 4, 2020: $44.97
5-year return: 3,498%
Closing price June 8, 2020: $11.80
Closing price June 4, 2020: $378.10
5-year return: 3,104%
Closing price June 8, 2020: $1.18
Closing price June 4, 2020: $29.95
5-year return: 2,438%
Closing price June 8, 2020: $3.97
Closing price June 4, 2020: $84.89
5-year return: 2,038%
Closing price June 8, 2020: $10.51
Closing price June 4, 2020: $193.81
5-year return: 1,744%
Closing price June 8, 2020: $6.57
Closing price June 4, 2020: $119.90
5-year return: 1,725%
Closing price June 8, 2020: $5.35
Closing price June 4, 2020: $91.66
5-year return: 1,613%
Closing price June 8, 2020: $2.71
Closing price June 4, 2020: $46.16
5-year return: 1,603%
Closing price June 8, 2020: $10.37
Closing price June 4, 2020: $122.82
5-year return: 1,084%
More From GOBankingRates
3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025
8 Common Mistakes Retirees Make With Their Social Security Checks
10 Cars That Outlast the Average Vehicle
This article originally appeared on GOBankingRates.com: See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Gold Advances on Middle East Tensions and Trump's Tariff Pledge
(Bloomberg) -- Gold gained for a second day on increased tensions in the Middle East, with its haven status also supported by President Donald Trump's comments that he will inform trading partners on tariff rates within two weeks. Shuttered NY College Has Alumni Fighting Over Its Future Trump's Military Parade Has Washington Bracing for Tanks and Weaponry NYC Renters Brace for Price Hikes After Broker-Fee Ban NY Long Island Rail Service Resumes After Grand Central Fire NYC Mayoral Candidates All Agree on Building More Housing. But Where? Bullion rose as much as 0.6% to around $3,373 an ounce, extending a 1% gain from the earlier session when it was also boosted by a declining dollar. Buying interest increased after the US ordered some embassy staff to depart Baghdad and allowed military families to leave the Middle East, after Iran threatened to attack US bases if talks over its nuclear program fell through. Separately, Trump said he intended to send letters to trading partners in the next one to two weeks setting unilateral tariff rates, ahead of a July 9 deadline to reimpose higher duties on dozens of economies. The president also said a trade framework with China has been completed, with levies between the two largest economies to be maintained at their current levels. Uncertainties over global trade tensions and heightened geopolitical risks have rattled markets this year, boosting gold's allure as a store of value in turbulent times and powering a year-to-date advance of 28%. The precious metal, which reached an all-time high in April, has also been supported by increased central-bank buying. Spot gold was up 0.3% to $3,364.43 as of 7:59 a.m. Singapore time. The Bloomberg Dollar Spot Index was steady after falling 0.4% on Wednesday. Silver, platinum and palladium all gained. New Grads Join Worst Entry-Level Job Market in Years The Spying Scandal Rocking the World of HR Software American Mid: Hampton Inn's Good-Enough Formula for World Domination The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again ©2025 Bloomberg L.P.
Business of Fashion
35 minutes ago
- Business of Fashion
Zara Owner Inditex Posts Slowing Growth
Zara owner Inditex SA reported a muted start to the second quarter and warned that foreign-exchange fluctuations could have a greater impact on results this year than anticipated. The shares tumbled. Revenue at the world's largest listed clothing retailer rose 6% in the five weeks to June 9, excluding currency effects. That was weaker than last year's start to the summer season, the Arteixo, Spain-based retailer said on Wednesday. 'The release fails to dispel concerns on slowing growth,' analysts at Barclays wrote in a note. The company's shares fell as much as 6.4 percent in early Madrid trading. The stock is down about 4.7 percent since the start of the year. Even though current trading is tracking higher than the 4.2 percent sales growth recorded in the first quarter, the latest numbers suggest that Inditex, like its peers, is not immune to a drop in demand prompted by the global trade war. The company has fared better than many of its rivals by keeping tighter controls on inventory, enabling it to remain nimble in a fickle fashion industry, but its sales-growth rates have headed down sharply from the post-pandemic boom era. Swedish rival Hennes & Mauritz AB posted disappointing first-quarter results because of stockpiles of unsold clothing. Foreign-exchange swings are likely to be a greater-than-expected drag on revenue this year, Inditex warned. The company expects currency fluctuations to shave 3 percent off sales this year, up from 1 percent it had expected previously. The adjustment follows a notable depreciation in both the US dollar and the Mexican peso against the euro, shrinking international earnings when converted back to the company's home currency. Other retailers have also signalled the cooling effect FX swings are having with H&M citing a strong kroner as another reason for its weak first-quarter. Last month, German sneaker brand Puma AG said the effect of tariffs and currency fluctuations was challenging to manage. The global garment industry tends to be a dollar-denominated business, which can particularly affect European retailers when they translate earnings back into local currencies. Inditex first spooked the market in March when it signalled a weaker start to its fiscal year, provoking a 7.5 percent fall — the biggest single-day plunge in its shares in five years. In its first quarter ended April 30, operating profit was in line with analyst estimates, while revenue was below expectations. The retailer said costs grew 2.3 percent in the period, rising faster than the 1.5 percent increase in revenue, including currency swings. Asked about the effect of President Donald Trump's tariffs, Inditex said it would use its broad range of suppliers, including those close to home in Spain, Portugal, Turkey and Morocco to manage the situation. 'In any case, I'd say that we see growth opportunities globally, not just in one market,' said Investor Relations Director Gorka Garcia-Tapia Yturriaga on a call with analysts. Over the last few years, the company has invested in both expanding its network of stores and also on refurbishing existing outlets to ensure a better shopping experience for customers. The company plans to spend €1.8 billion ($2 billion) again this year on store improvements and technology, along with an additional €900 million to expand its logistics network. By Clara Hernanz Lizarraga Learn more: The Brewing Controversy Over the Cotton in Your T-Shirt Zara owner Inditex, the world's largest fast fashion company, is ditching the industry's biggest sustainable cotton scheme amid a deforestation scandal and a wider push to prioritise organic fibres.
